KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abbott Laboratories (ABT) Tax Provisions (2016 - 2025)

Historic Tax Provisions for Abbott Laboratories (ABT) over the last 17 years, with Q3 2025 value amounting to $536.0 million.

  • Abbott Laboratories' Tax Provisions rose 8231.29% to $536.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.8 billion, marking a year-over-year decrease of 67754.7%. This contributed to the annual value of -$6.4 billion for FY2024, which is 77895.86% down from last year.
  • Per Abbott Laboratories' latest filing, its Tax Provisions stood at $536.0 million for Q3 2025, which was up 8231.29% from $371.0 million recorded in Q2 2025.
  • Abbott Laboratories' Tax Provisions' 5-year high stood at $536.0 million during Q3 2025, with a 5-year trough of -$7.2 billion in Q4 2024.
  • Its 5-year average for Tax Provisions is -$82.9 million, with a median of $294.0 million in 2024.
  • As far as peak fluctuations go, Abbott Laboratories' Tax Provisions skyrocketed by 154545.45% in 2021, and later tumbled by 368159.2% in 2024.
  • Over the past 5 years, Abbott Laboratories' Tax Provisions (Quarter) stood at $338.0 million in 2021, then fell by 15.09% to $287.0 million in 2022, then fell by 29.97% to $201.0 million in 2023, then crashed by 3681.59% to -$7.2 billion in 2024, then soared by 107.45% to $536.0 million in 2025.
  • Its last three reported values are $536.0 million in Q3 2025, $371.0 million for Q2 2025, and $453.0 million during Q1 2025.